IRIS

BeyPro1: A phase II single-arm study for the treatment after recurrence of advanced melanoma patients harboring the (V600)BRAF mutation and pretreated with vemurafenib, with the association of vemurafenib plus fotemustine / Ascierto, P. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - 32:15(2014).

BeyPro1: A phase II single-arm study for the treatment after recurrence of advanced melanoma patients harboring the (V600)BRAF mutation and pretreated with vemurafenib, with the association of vemurafenib plus fotemustine

Ascierto P
2014
2014
BeyPro1: A phase II single-arm study for the treatment after recurrence of advanced melanoma patients harboring the (V600)BRAF mutation and pretreated with vemurafenib, with the association of vemurafenib plus fotemustine / Ascierto, P. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - 32:15(2014).
1.1 Articolo in rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/1014322
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact